| 14 July 2022 | Best practice management of patients with chronic obstructive pulmonary disease: A case-based review
| Vega-Olivo, M; Halpin, DMG; Han, MK; et al. |
| 15 August 2022 | Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
| Thompson, PJ; Criner, GJ; Dransfield, MT; et al. |
| 17 July 2022 | Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis
| Ismaila, AS; Haeussler, K; Czira, A; et al. |
| 1 March 2023 | Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary
| Agustí, A; Celli, BR; Criner, GJ; et al. |
| 1 April 2023 | Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary
| Agustí, A; Celli, BR; Criner, GJ; et al. |
| 1 April 2023 | Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary
| Agustí, A; Celli, BR; Criner, GJ; et al. |
| 1 March 2023 | Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary
| Agustí, A; Celli, BR; Criner, GJ; et al. |
| 1 April 2023 | Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary
| Agustí, A; Celli, BR; Criner, GJ; et al. |
| 8 December 2022 | Mortality risk and serious cardiopulmonary events in moderate-to-severe COPD: Post hoc analysis of the IMPACT trial
| Wells, JM; Criner, GJ; Halpin, DMG; et al. |
| 1 April 2023 | A response to: Letter to the editor regarding "Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis"
| Ismaila, AS; Haeussler, K; Malmenäs, M; et al. |
| 11 November 2022 | Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis
| Bardsley, S; Criner, GJ; Halpin, DMG; et al. |
| 25 July 2022 | Single-inhaler triple therapy in patients with advanced COPD: Bayesian modeling of the healthcare resource utilization data and associated costs from the IMPACT trial
| Gabrio, A; Gunsoy, NB; Baio, G; et al. |
| 14 September 2022 | Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: Post hoc analysis from the IMPACT trial
| Dransfield, MT; Criner, GJ; Halpin, DMG; et al. |
